Long-term treatment with acarbose for the treatment of reactive hypoglycemia
| Autor: | Taylan Kabalak, Mehmet Tüzün, Firat Bayraktar, Candeger Yilmaz, Şevki Çetinkalp, Ahmet Gokhan Ozgen, Füsun Hamulu |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Type 2 diabetes Hypoglycemia Diabetes mellitus Internal medicine Humans Insulin Medicine Glycoside Hydrolase Inhibitors Enzyme Inhibitors Acarbose Glucose tolerance test Reactive hypoglycemia C-Peptide medicine.diagnostic_test business.industry Glucose Tolerance Test Middle Aged medicine.disease Psychiatry and Mental health Clinical Psychology Endocrinology Postprandial Female business medicine.drug |
| Zdroj: | Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 3:136-140 |
| ISSN: | 1590-1262 1124-4909 |
| DOI: | 10.1007/bf03340001 |
| Popis: | Objective: Acarbose, a potent alpha-glucosidase inhibitor, provides a new concept for the treatment of metabolic disorders, and particularly diabetes mellitus. It reduces the postprandial blood glucose increment and insulin response. For this reason the drug has been successfully used not only in the treatment of type 1 and type 2 diabetes, but also in the management of reactive hypoglycemia and dumping syndrome. The primary aim of the present study is to evaluate the long-term effect of acarbose in reducing hypoglycemic symptoms and influencing laboratory measurements in patients with the diagnosis of reactive hypoglycemia. Design and Methods: 21 non-obese (BMI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink